NewsRx

Search our medical news database

Stem Cell Transplantation

Reduced intensity transplantation encouraging in indolent lymphoproliferative disorders

Published in Clinical Oncology Week, September 11th, 2006

Clinical data is encouraging for reduced intensity stem cell transplantation for indolent lymphoproliferative disorders.

"Indolent lymphoproliferative disorders are incurable with conventional chemotherapy. Exploring the potential of allogeneic transplantation to eradicate disease has therefore been of interest for some time.

"This review reports on recent developments in this field to evaluate the current status of stem cell transplantation in the management of these conditions," wrote investigators in England.

According to K.J. Thomson and colleagues at Royal Free & University College Medical School in London, "Most recent...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook